Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in Spain.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in Korea.
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art prostate cancer imaging tools. The NOBLE Registry is co-supported by Telix and Brussels-based Oncidium Foundation.
ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate cancer.
Telix Japan – Upcoming Events in November
We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021.
Activities Report and Appendix 4C for September 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual Meeting
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021.